Literature DB >> 7769842

Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines.

J D Bailly1, C Muller, J P Jaffrézou, C Demur, G Gassar, C Bordier, G Laurent.   

Abstract

In a panel of acute myeloblastic leukemia (AML) cell lines, representative of distinct differentiation stages, we investigated the possible correlation between drug-resistance and both expression and function of the multidrug resistance (MDR)-related P-glycoprotein (P-gp). The AML cell lines were KG1a, KG1, TF1, HEL, ML1, and two non drug-selected P-gp positive subclones originating from HL-60 (HL-60JD) and U937 (U937AQ). All these cells overexpressed the mdr1 gene (analyzed by RT-PCR) and displayed variable levels of P-gp expression. Flow cytometric semi-quantitative evaluation of P-gp with two P-gp specific monoclonal antibodies (MRK16 and UIC2) showed the following P-gp expression hierarchy: TF1 < KG1a < HEL < KG1 < HL-60JD < ML1 < U937AQ; the latter expressing 13 times more P-gp than TF1. When P-gp function was assessed by Rhodamine 123 (Rh123) efflux kinetics, we found that only KG1a and KG1 cells, which have an early (immature) CD34+ CD33- CD38- phenotype, and to a lesser extent TF1, with an intermediate (CD34+ CD33+ CD38+) phenotype, displayed significant P-gp activity which could be inhibited by both verapamil and SDZ PSC 833. In contrast, the other more mature CD33+ CD34- AML cell lines presented no Rh123 efflux capacity although they expressed higher P-gp levels. Daunorubicin (DNR) accumulation studies showed that inhibitors of P-gp increased DNR accumulation only in the immature AML cells whereas they had no impact on the mature AML cell lines. MTT drug cytotoxicity assay confirmed that the immature AML cells were 10-15-fold more resistant to DNR than the mature AML cells. Although P-gp inhibitors were able to increase the cytotoxicity of DNR in AML cells which displayed functional P-gp, they could not increase DNR cytotoxicity to levels comparable to that of the CD34- CD33+ cells, suggesting that DNR resistance of immature AML cells may not solely be related to P-gp. With drug-selection, AML subclones displayed higher levels of P-gp expression and higher extruding capacities, and therefore chemoresistance, and this independently of their initial differentiation phenotype. Finally, this study provides evidence for a lack of correlation between expression and function of P-gp in AML cells; this relationship being dependent upon leukemic cell differentiation in unselected myeloid leukemic cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769842

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  22 in total

1.  BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore.

Authors:  Angela Risso; Enrico Braidot; Maria Concetta Sordano; Angelo Vianello; Francesco Macrì; Barbara Skerlavaj; Margherita Zanetti; Renato Gennaro; Paolo Bernardi
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

2.  Phosphatidylcholine-specific phospholipase C and phospholipase D are respectively implicated in mitogen-activated protein kinase and nuclear factor kappaB activation in tumour-necrosis-factor-alpha-treated immature acute-myeloid-leukaemia cells.

Authors:  I Plo; D Lautier; T Levade; H Sekouri; J P Jaffrézou; G Laurent; A Bettaïeb
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

Review 3.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

4.  17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.

Authors:  Jennifer M Napper; Vincent E Sollars
Journal:  Leuk Res       Date:  2010-06-19       Impact factor: 3.156

5.  Development of analytical methods for multiplex bio-assay with inductively coupled plasma mass spectrometry.

Authors:  Olga I Ornatsky; Robert Kinach; Dmitry R Bandura; Xudong Lou; Scott D Tanner; Vladimir I Baranov; Mark Nitz; Mitchell A Winnik
Journal:  J Anal At Spectrom       Date:  2008       Impact factor: 4.023

6.  Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance.

Authors:  Y P Hu; J Robert
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

7.  The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver.

Authors:  S Eyal; J G Lamb; M Smith-Yockman; B Yagen; E Fibach; Y Altschuler; H S White; M Bialer
Journal:  Br J Pharmacol       Date:  2006-08-07       Impact factor: 8.739

8.  Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity.

Authors:  Jean-Marie Nicolas; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2019-05-28       Impact factor: 4.009

9.  Erlotinib antagonizes ABC transporters in acute myeloid leukemia.

Authors:  Elodie Lainey; Marie Sébert; Sylvain Thépot; Marie Scoazec; Cyrielle Bouteloup; Carole Leroy; Stéphane De Botton; Lorenzo Galluzzi; Pierre Fenaux; Guido Kroemer
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

10.  The role of multidrug resistance protein 1 (MRP1) in transport of fluorescent anions across the human erythrocyte membrane.

Authors:  B Rychlik; A Balcerczyk; A Klimczak; G Bartosz
Journal:  J Membr Biol       Date:  2003-05-15       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.